Witryna6 sty 2024 · Data are from the IMS Health PharMetrics Plus Database, which contains individual-level, de-identified health care claims information from employers, hospitals, and health plans on more than 150 million commercially insured patients in the United States. Data were extracted for medical claims for VWD (ICD-9 286.4), other bleeding … WitrynaObjectives: To estimate biologic cost per effectively treated patient with rheumatoid arthritis (RA) using a claims-based algorithm for effectiveness. Methods: Patients with …
IQVIA PharMetrics® Plus - IQVIA
Witryna14 lip 2024 · This was a retrospective cohort study using IQVIA PharMetrics® Plus health plan claims database. The aggregated IQVIA PharMetrics Plus database is a nationally representative commercial claims database which comprises adjudicated medical and pharmacy claims of patients in the USA and is sourced directly from the … Witryna1 wrz 2014 · Methods: Adult patients with ≥1 diagnosis of MCL and ≥1 claim for a medication used to treat MCL were identified in the IMS PharMetrics Plus database (January 2008 - September 2013). Patients were excluded if they had evidence of a non-hematologic malignancy, used a non-MCL antineoplastic agent, or received a stem … popup in power apps
Prevalence of rheumatoid arthritis in the United States adult
WitrynaMethods: NVAF patients who initiated apixaban, rivaroxaban, dabigatran, or warfarin were identified from the IMS Pharmetrics Plus database (January 1, 2013 … Witryna6 sty 2024 · Methods: Patients with a VWD diagnosis who were users of or candidates for von Willebrand factor replacement were identified from the IMS PharMetrics Plus … Witryna20 maj 2016 · Methods: Two retrospective cohort studies were independently conducted using IMS PharMetrics Plus databases and MarketScan commercial and Medicare supplemental databases. Patients included those aged ≥ 18 years who had ≥ 1 metastatic melanoma diagnosis and ≥ 1 claim for any systemic therapies from July 1, … popup in react native